DOI 10.1038/s41598-026-36992-3
Cost of illness of Mycoplasma genitalium in Australia: an incidence-based approach incorporating resistance-guided therapy.
Аннотация
As macrolide-resistant Mycoplasma genitalium (MG) becomes more prevalent, resistance-guided therapy (RGT) for MG has been recommended in clinical guidelines to improve first-line antibiotic selection and increase cure rates. This study adopted an incidence-based approach and a healthcare sector perspective to measure the cost of illness of MG in Australia. Two management strategies, RGT and non-RGT, were examined. A decision tree model was developed to replicate the clinical pathways among non-pregnant women, men who have sex with men (MSM) and men who have sex with women (MSW). The burden of managing a woman diagnosed with MG was lower under RGT compared to non-RGT (AUD 249 vs. 283). For MSM, the expected per-person cost was AUD 240 and AUD 279 under RGT and non-RGT. For MSW, non-RGT would cost an additional AUD 23. Overall, this study found that the economic burden of MG under RGT is lower than under non-RGT for both women and men in Australia. RGT offers cost savings while improving MG clinical management and helping to slow the spread of macrolide resistance.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.